Table 4.
T-cell proliferation following treatment with MAP purified protein derivative (PPD) or phytohemagglutinin (PHA) and RHB-104, and its major components.
| Treatment | T-cell Proliferation (OD at 450 nm) |
Relative T-cell Proliferation |
|---|---|---|
| Control (no PHA or MAP PPD) | 0.061 | 1.00 ± 0.003 |
| PHA Control | 0.219 | 3.60 ± 0.059 |
| PHA + 1.0 µg/mL RHB-104 | 0.046 | 0.75 ± 0.002 *,† |
| PHA + 0.63 µg/mL CLA | 0.066 | 1.09 ± 0.021 * |
| PHA + 0.30 µg/mL RIF | 0.060 | 0.99 ± 0.013 * |
| MAP PPD Control | 0.189 | 3.12 ± 0.087 |
| MAP PPD + 1.0 µg/mL RHB-104 | 0.066 | 1.09 ± 0.010 *,† |
| MAP PPD + 0.63 µg/mL CLA | 0.107 | 1.76 ± 0.060 * |
| MAP PPD + 0.30 µg/mL RIF | 0.113 | 1.86 ± 0.034 * |
* p value < 0.05 compared to PHA or MAP PPD control; † p value < 0.05 compared to CLA and RIF treatment.